Iniciar sesión Regístrese gratis

Cotinga Pharmaceuticals Capitalización de mercado

¿Qué es el Capitalización de mercado de Cotinga Pharmaceuticals?

El Capitalización de mercado de Cotinga Pharmaceuticals, Inc. es $605.64k

¿Cuál es la definición de Capitalización de mercado ?



La capitalización de mercado es el valor de mercado en un momento en el tiempo de las acciones en circulación de una empresa que cotiza en bolsa, que es igual al precio de la acción en ese punto de tiempo por el número de acciones en circulación .

As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.

Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.

The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.

Capitalización de mercado de compañías en Sector Health Care en TSXV en comparadas con Cotinga Pharmaceuticals

¿Qué hace Cotinga Pharmaceuticals?

Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.

Empresas con capitalización de mercado similar a Cotinga Pharmaceuticals